Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Halozyme TherapeuticsHALO +1.35%93 Cyclically Adjusted PB Ratio is 51.21 as of Jul. 24, 2026, which is 14% above its 10-year median of 44.97. GuruFocus rates HALO with a GF Scoreâ„¢ of 93/100 and a GF Valueâ„¢ of $91.87 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 699 Biotechnology companies, Halozyme Therapeutics ranks worse than 98.28% on this metric.
The historical rank and industry rank for Halozyme Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:
HALO'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 25.64 Med: 44.97 Max: 79.11
Current: 50.4
During the past years, Halozyme Therapeutics's highest Cyclically Adjusted PB Ratio was 79.11. The lowest was 25.64. And the median was 44.97.
HALO's Cyclically Adjusted PB Ratio is ranked worse than 98.28% of 699
companies
in the Biotechnology industry
Industry Median: 1.63
vs HALO: 50.40
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Halozyme Therapeutics's adjusted book value per share data for the three months ended in Mar. 2026 was $1.853. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $1.60 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Halozyme Therapeutics (NAS:HALO) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Halozyme Therapeutics Cyclically Adjusted PB Ratio Related Terms
Halozyme Therapeutics Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for Halozyme Therapeutics's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Halozyme Therapeutics Cyclically Adjusted PB Ratio Chart
HALO vs KYMR, IBRX, PRAX: Cyclically Adjusted PB Ratio Comparison
For the Biotechnology subindustry, Halozyme Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Halozyme Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Halozyme Therapeutics's Cyclically Adjusted PB Ratio falls into.
Halozyme Therapeutics Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 51.21 mean?
Halozyme Therapeutics (HALO) has a Cyclically Adjusted PB Ratio of 51.21 as of Jul. 24, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Halozyme Therapeutics and its competitors. This is 14% above median its historical median of 44.97. Over the past decade, Halozyme Therapeutics' Cyclically Adjusted PB Ratio has ranged from 25.64 to 79.11. According to the industry distribution chart, Halozyme Therapeutics ranks #687 out of 699 companies in the Biotechnology industry, placing it in the top 98.3%.
Is Halozyme Therapeutics' Cyclically Adjusted PB Ratio too high?
Halozyme Therapeutics' current Cyclically Adjusted PB Ratio of 51.21 is 14% above median its 10-year median of 44.97. Over the past 10 years, this metric has ranged from a low of 25.64 to a high of 79.11. The Biotechnology industry median Cyclically Adjusted PB Ratio is 1.63. Halozyme Therapeutics' value of 51.21 is 3041.7% above this industry median. Based on the distribution chart, Halozyme Therapeutics ranks #687 out of 699 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Halozyme Therapeutics has a GF Scoreâ„¢ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' Cyclically Adjusted PB Ratio compare to KYMR and IBRX?
According to the Biotechnology industry distribution chart, Halozyme Therapeutics ranks #687 out of 699 companies for Cyclically Adjusted PB Ratio. This places Halozyme Therapeutics in the lower half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.63. Halozyme Therapeutics' value of 51.21 is 3041.7% above this benchmark. Historically, Halozyme Therapeutics' own Cyclically Adjusted PB Ratio has ranged from 25.64 to 79.11 over the past decade. While the company's 10-year median is 44.97 vs. the industry median of 1.63, Halozyme Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Biotechnology company?
The median Cyclically Adjusted PB Ratio among Biotechnology companies is 1.63, based on 699 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Halozyme Therapeutics's current Cyclically Adjusted PB Ratio of 51.21 is 3041.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Halozyme Therapeutics and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PB Ratio is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Halozyme Therapeutics's current Cyclically Adjusted PB Ratio is 51.21, which is 14% above median its own 10-year median of 44.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (HALO) is currently considered Modestly Undervalued. The stock's GF Value™ is $91.87, compared to a current price of $81.93 — trading 10.8% below its estimated fair value. The current Cyclically Adjusted PB Ratio is 51.21, which is 14% above median its 10-year median of 44.97 and 3041.7% above the Biotechnology industry median of 1.63. Halozyme Therapeutics' overall GF Score™ is 93/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Halozyme Therapeutics (HALO), the current Cyclically Adjusted PB Ratio is 51.21 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Halozyme Therapeutics (HALO) Overvalued in 2026?
Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be undervalued.
The current stock price of $81.93 is trading 10.8% below its estimated GF Value™ of $91.87.
GuruFocus considers Halozyme Therapeutics to be Modestly Undervalued.
Key valuation signals for HALO:
Cyclically Adjusted PB Ratio: 51.21 (14% above median its 10-year median of 44.97)
GF Value™: $91.87 vs. price of $81.93 (10.8% below fair value)
Industry Position: 3041.7% above the Biotechnology median (#687 of 699)
No single metric tells the full story. See the HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
93GF Score
Get the complete analysis for HALO
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HALO has been successfully added to your 
